Harnessing the power of clinician judgement. Identifying risk of deteriorating and dying in people with a haematological malignancy: A Delphi study.


Journal

Journal of advanced nursing
ISSN: 1365-2648
Titre abrégé: J Adv Nurs
Pays: England
ID NLM: 7609811

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 04 02 2018
revised: 21 08 2018
accepted: 09 10 2018
pubmed: 31 10 2018
medline: 7 5 2019
entrez: 31 10 2018
Statut: ppublish

Résumé

To provide expert consensus on the clinical indicators that signal a person with a haematological malignancy is at high risk of deteriorating and dying. Identification of people who are at risk of deteriorating and dying is essential to facilitate patient autonomy, appropriate treatment decisions, and effective end-of-life care. A three-step modified Delphi approach. The study was conducted over 6 months (September 2015-March 2016) to gather opinion from an international panel of experts (N = 27) on the clinical indicators that signal a person with a haematological malignancy is at high risk of deteriorating and dying. The first round was informed by a systematic review of prognostic factors present in the final months of life for people with a haematological malignancy. Consensus was achieved if 70% of responses fell within two points on a seven-point Likert-type scale. Consensus was achieved on the following 11 clinical indicators: (a) advancing age; (b) declining performances status; (c) presence of co-morbidities; (d) disease status; (e) persistent infections (bacterial and viral); (f) fungal infections; (g) severe graft versus host disease; (h) requiring high care; (i) signs of frailty; (j) treatment limitations; and (k) anorexia and/or weight loss. Consensus was also achieved on associated themes and statements for each indicator. The findings of this study indicate that subjective clinician-assessed indicators that are contextually relevant to the nature of haematological malignancies are markers of risk. This study has provided valuable preliminary findings on the topic and will inform future research.

Sections du résumé

AIM OBJECTIVE
To provide expert consensus on the clinical indicators that signal a person with a haematological malignancy is at high risk of deteriorating and dying.
BACKGROUND BACKGROUND
Identification of people who are at risk of deteriorating and dying is essential to facilitate patient autonomy, appropriate treatment decisions, and effective end-of-life care.
DESIGN METHODS
A three-step modified Delphi approach.
METHODS METHODS
The study was conducted over 6 months (September 2015-March 2016) to gather opinion from an international panel of experts (N = 27) on the clinical indicators that signal a person with a haematological malignancy is at high risk of deteriorating and dying. The first round was informed by a systematic review of prognostic factors present in the final months of life for people with a haematological malignancy. Consensus was achieved if 70% of responses fell within two points on a seven-point Likert-type scale.
FINDINGS RESULTS
Consensus was achieved on the following 11 clinical indicators: (a) advancing age; (b) declining performances status; (c) presence of co-morbidities; (d) disease status; (e) persistent infections (bacterial and viral); (f) fungal infections; (g) severe graft versus host disease; (h) requiring high care; (i) signs of frailty; (j) treatment limitations; and (k) anorexia and/or weight loss. Consensus was also achieved on associated themes and statements for each indicator.
CONCLUSION CONCLUSIONS
The findings of this study indicate that subjective clinician-assessed indicators that are contextually relevant to the nature of haematological malignancies are markers of risk. This study has provided valuable preliminary findings on the topic and will inform future research.

Identifiants

pubmed: 30375000
doi: 10.1111/jan.13889
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

161-174

Subventions

Organisme : National Health and Medical Research Council Centre for Research Excellence in End-of-Life Care
Organisme : Queensland University of Technology
Organisme : Royal Brisbane and Women's Hospital
Organisme : Centaur Memorial Fund for Nurses

Informations de copyright

© 2018 John Wiley & Sons Ltd.

Auteurs

Elise Button (E)

Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
School of Nursing, Queensland University of Technology, Brisbane, Queensland, Australia.
Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia.
Sigma Theta Tau International, 482 Phi Delta at-Large Chapter, Brisbane, Queensland, Australia.

Nicole C Gavin (NC)

Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
School of Nursing, Queensland University of Technology, Brisbane, Queensland, Australia.

Raymond J Chan (RJ)

Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia.
Cancer Nursing, Princess Alexandra Hospital and Queensland University of Technology, Brisbane, Queensland, Australia.

Shirley Connell (S)

School of Nursing, Queensland University of Technology, Brisbane, Queensland, Australia.
Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia.

Jason Butler (J)

Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
Hematology and Bone Marrow Transplant Unit, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.

Patsy Yates (P)

Cancer Care Services, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
School of Nursing, Queensland University of Technology, Brisbane, Queensland, Australia.
Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH